PDCD1 and cancer: However, this success is tempered by the unpredictable nature of responses (seen in only 20–60% of patients across these cancer indications7) and the more frequent severe immune-related adverse effects experienced with CICB when compared to anti-PD-1 or anti-PD-L1 monotherapy8.